Biologics refer to various forms of preparations that use carbon based organisms with medical research value as raw materials, manufactured through traditional or modern biotechnology, and act on the prevention, treatment, and diagnosis of various physiological symptoms in the human body. ‌

Overview of Market Development

Development status: The Middle East region includes over 18 countries with a common culture and similar healthcare systems, a large population, and enormous economic development potential. In recent years, the Middle East has vigorously developed the medical innovation industry and frequently released relevant policies, resulting in a steady development of its pharmaceutical market. At the same time, the region has introduced the FDA system in drug regulation, aligning regulatory standards with international standards, and has a shortage of high-end talents with excellent research and development capabilities. According to our research data, the market size of biologics in the Middle East is expected to reach $21.22 billion in 2024, an increase of 9.27% compared to 2023.

Outlook forecast: Influenced by the continuous growth of the global biopharmaceutical market and the attention and reasonable planning of the biopharmaceutical industry by the governments in the Middle East, it is expected that the biologics market in the Middle East will experience significant growth. According to our prediction, the market size of biologics in the Middle East is expected to increase to $32.62 billion by 2029. The CAGR for 2024-2029 is estimated to be 8.97%.

Analysis of Market Competition Pattern

From the perspective of market competition, the concentration of the biopharmaceutical market in the Middle East is moderate. Data shows that in 2023, the top 3 companies in the industry had a total revenue of $6.15 billion for biologics, with a total share of 31.65%; The total revenue of the top 6 companies was $10.82 billion, with a total share of 55.71%. The top three companies were Roche, Sanofi and Novartis. In 2023, these three companies accounted for 11.15%, 10.39%, and 10.11% of the biopharmaceutical market revenue in the Middle East market, respectively.

Segmented Market Analysis

By type, biologics can be divided into medical biologics and health biologics. Medical biologics such as vaccines and adalimumab injections are mainly used for the treatment of diseases; Health supplements such as calcium gluconate oral solution, calcium lactate tablets, etc. are mainly used to enhance human health and prevent diseases. Among them, medical biologics dominate the market, with an expected market share of 68.63% by 2024.

From a national perspective, Iran is the largest revenue market for biologics in the Middle East region. Data shows that the estimated revenue of Iran's biologics market in 2024 is $3.38 billion, with an estimated market share of 15.94%; Saudi Arabia is expected to rank second with a share of 13.45%.

	Market Revenue (Billion USD)	Market Share
Segmented by Type
Medical Biologics	14.57	68.63%
Health Biologics	6.66	31.37%
Segmented by Countries
Israel	1.08	5.09%
Iran	3.38	15.94%
Qatar	0.46	2.17%
Saudi Arabia	2.86	13.45%
UAE	0.80	3.76%
Others	12.65	59.59%